Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Staphylococcus aureus | Peptide deformylase | Starlite/ChEMBL | References |
Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4) | Peptide deformylase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | adipor-like receptor | Peptide deformylase | 203 aa | 163 aa | 23.9 % |
Trichomonas vaginalis | abca6, putative | Peptide deformylase | 183 aa | 162 aa | 25.3 % |
Trypanosoma cruzi | hypothetical protein | Peptide deformylase | 183 aa | 155 aa | 22.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.008 | 0.1179 | 1 |
Echinococcus granulosus | voltage gated potassium channel | 0.0023 | 0.0135 | 0.1145 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.0023 | 0.0135 | 0.1145 |
Trypanosoma cruzi | polypeptide deformylase-like protein, putative | 0.0213 | 0.3636 | 0.5 |
Trypanosoma cruzi | polypeptide deformylase-like protein, putative | 0.0213 | 0.3636 | 0.5 |
Mycobacterium tuberculosis | Probable polypeptide deformylase Def (PDF) (formylmethionine deformylase) | 0.0558 | 1 | 0.5 |
Plasmodium vivax | peptide deformylase, putative | 0.0558 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0069 | 0.0985 | 0.8354 |
Toxoplasma gondii | hypothetical protein | 0.0558 | 1 | 0.5 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.008 | 0.1179 | 1 |
Wolbachia endosymbiont of Brugia malayi | peptide deformylase | 0.0558 | 1 | 0.5 |
Trypanosoma brucei | Polypeptide deformylase 1 | 0.0213 | 0.3636 | 0.5 |
Trypanosoma cruzi | Peptide deformylase 2, putative | 0.0213 | 0.3636 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0023 | 0.0135 | 0.1145 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0087 | 0.1314 | 1 |
Mycobacterium ulcerans | peptide deformylase | 0.0558 | 1 | 0.5 |
Loa Loa (eye worm) | voltage and ligand gated potassium channel | 0.008 | 0.1179 | 1 |
Brugia malayi | Voltage-gated potassium channel, HERG (KCNH2)-related. C. elegans unc-103 ortholog | 0.008 | 0.1179 | 1 |
Plasmodium falciparum | peptide deformylase | 0.0558 | 1 | 0.5 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0074 | 0.1082 | 1 |
Echinococcus multilocularis | voltage gated potassium channel | 0.0023 | 0.0135 | 0.1145 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0074 | 0.1082 | 1 |
Leishmania major | polypeptide deformylase-like protein, putative | 0.0213 | 0.3636 | 0.5 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0023 | 0.0135 | 0.1028 |
Brugia malayi | Voltage-gated potassium channel, EAG (KCNH1)-related. C. elegans egl-2 ortholog | 0.0023 | 0.0135 | 0.1145 |
Trypanosoma cruzi | Peptide deformylase 2, putative | 0.0213 | 0.3636 | 0.5 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0023 | 0.0135 | 0.1028 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0087 | 0.1314 | 1 |
Trypanosoma brucei | Peptide deformylase 2 | 0.0213 | 0.3636 | 0.5 |
Mycobacterium leprae | PROBABLE POLYPEPTIDE DEFORMYLASE DEF (PDF) (FORMYLMETHIONINE DEFORMYLASE) | 0.0558 | 1 | 0.5 |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.0023 | 0.0135 | 0.1145 |
Treponema pallidum | polypeptide deformylase (def) | 0.0558 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.26 nM | Inhibition of Streptococcus pneumoniae PDF assessed as formate release from fMAS peptide substrate after 20 mins by formate dehydrogenase coupled assay | ChEMBL. | 22579486 |
IC50 (binding) | = 1.4 nM | Inhibition of Staphylococcus aureus PDF assessed as formate release from fMAS peptide substrate after 20 mins by formate dehydrogenase coupled assay | ChEMBL. | 22579486 |
Stability (ADMET) | = 57.5 % | Metabolic stability of the compound in human blood assessed as compound remaining at 2000 ng/mL after 2 hrs | ChEMBL. | 22579486 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.